Pharmaceutical

Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-9574?

AZD-9574 is a small molecule commercialized by AstraZeneca, with a leading Phase II program in Vaginal Cancer.

Apr 17, 2024 - 00:00
AZD-9574 is a small molecule commercialized by AstraZeneca, with a leading Phase II program in Vaginal Cancer.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Novartis’s XXB...

Next Article

Risk adjusted net present value: What is the current valuation of Merck’s MK-1084?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ebola vaccine cuts fatality even in people who were infected before the jab, new study shows

Ebola vaccine cuts fatality even in people who were inf...

Feb 13, 2024

Merck buys Mirus Bio to boost viral vector bioprocessing capacity

Merck buys Mirus Bio to boost viral vector bioprocessin...

Aug 3, 2024

Gilead, CHAI and Penta to enhance HIV treatment for children

Gilead, CHAI and Penta to enhance HIV treatment for chi...

Jul 15, 2023